Prevail Therapeutics gets FDA fast track designation for frontotemporal dementia gene therapy

Prevail Therapeutics (NASDAQ:PRVL) received FDA fast track designation for PR006, a gene therapy candidate designed to slow the progression of frontotemporal dementia with a GRN mutation.

Frontotemporal dementia is the second most common cause of dementia in people under the age of 65, after Alzheimer’s disease. Some five to 10% of frontotemporal dementia patients have the GRN mutation.

“The FDA’s decision to grant fast track designation for PR006 is an important step forward in our mission to deliver a potentially disease-modifying gene therapy to frontotemporal dementia patients with a GRN mutation as quickly as possible,” Dr. Asa Abeliovich, Prevail’s founder and CEO, said in a statement.

“Frontotemporal dementia with a GRN mutation progresses rapidly and there are currently no therapeutic options available. We believe PR006 has the potential to fill this unmet medical need and make a significant impact for patients,” he added.

Prevail announced an active IND for a Phase 1/2 clinical trial of PR006 earlier this month. 

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.